

# CITATION REPORT

List of articles citing

The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later

DOI: 10.1152/ajplung.00476.2019

American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1115-L1130.

**Source:** <https://exaly.com/paper-pdf/77210799/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper  | IF  | Citations |
|----|--|-----|-----------|
| 36 | [Pulmonary involvement in cancers]. <i>Pneumologie</i> , <b>2020</b> , 17, 1-9   | 0.1 |           |
| 35 | MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3 | 7         |
| 34 | The updated cancer paradigm of PAH: recognizing complexity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2020</b> , 318, L1111-L1114  | 5.8 | 1         |
| 33 | Perspective: pathobiological paradigms in pulmonary hypertension, time for reappraisal. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2020</b> , 318, L1131-L1137  | 5.8 | 3         |
| 32 | Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2020</b> , 318, L1140-L1141  | 5.8 | 0         |
| 31 | The cancer hypothesis of pulmonary arterial hypertension: the next ten years. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2020</b> , 318, L1138-L1139  | 5.8 | 0         |
| 30 | A cancer amidst us: the plexiform lesion in pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2020</b> , 318, L1142-L1144   | 5.8 | 1         |
| 29 | Pulmonary arterial hypertension and flavonoids: A role in treatment. <i>Chinese Journal of Physiology</i> , <b>2021</b> , 64, 115-124  | 1.6 | 1         |
| 28 | Pulmonary Hypertension as a Complication of Pediatric Cancer. <i>Global Pediatric Health</i> , <b>2021</b> , 8, 2333794x211009094  |     |           |
| 27 | Encyclopedia of Molecular Pharmacology. <b>2021</b> , 1-8  |     |           |
| 26 | Lungenbeteiligung bei Tumorkrankheiten. <i>Best Practice Onkologie</i> , <b>2021</b> , 16, 44-53   | 0   |           |
| 25 | Personalized Medicine for Pulmonary Hypertension:: The Future Management of Pulmonary Hypertension Requires a New Taxonomy. <i>Clinics in Chest Medicine</i> , <b>2021</b> , 42, 207-216   | 5.3 | 0         |
| 24 | Sex Dimorphism in Pulmonary Hypertension: The Role of the Sex Chromosomes. <i>Antioxidants</i> , <b>2021</b> , 10,   | 7.1 | 2         |
| 23 | Malignancy-Related Pulmonary Hypertension Presenting as a Pulmonary Veno-Occlusive-Like Syndrome: A Single-Center Case Series. <i>JACC: Case Reports</i> , <b>2021</b> , 3, 1044-1050  | 1.2 |           |
| 22 | Adenylate Kinase 4-A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1 $\beta$ Signaling Pathways. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,                           | 6.3 | 2         |
| 21 | EPAS1 (Endothelial PAS Domain Protein 1) Orchestrates Transactivation of Endothelial ICAM1 (Intercellular Adhesion Molecule 1) by Small Nucleolar RNA Host Gene 5 (SNHG5) to Promote Hypoxic Pulmonary Hypertension. <i>Hypertension</i> , <b>2021</b> , 78, 1080-1091 | 8.5 | 0         |
| 20 | Cancer and pulmonary hypertension: Learning lessons and real-life interplay. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202010   | 0.7 | 1         |

|    |   |      |   |
|----|---|------|---|
| 19 | Encyclopedia of Molecular Pharmacology. <b>2021</b> , 1328-1336   |      |   |
| 18 | Cancer and pulmonary hypertension: Learning lessons and real-life interplay. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202010  | 0.7  | 1 |
| 17 | The Effects of Ginsenoside Compound K on Pulmonary Arterial Hypertension Rats: Suppression of Vascular Remodeling and Inhibiting NF- $\kappa$ B/NLRP3 Inflammasome Signalling. <i>SSRN Electronic Journal</i> , <b>2022</b> , 1 |      |   |
| 16 | Insights on the Gut-Mesentery-Lung Axis in Pulmonary Arterial Hypertension: A Poorly Investigated Crossroad.. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2022</b> , ATVBAHA121316236                        | 9.4  | 0 |
| 15 | The Glycobiology of Pulmonary Arterial Hypertension.. <i>Metabolites</i> , <b>2022</b> , 12,  | 5.6  | 2 |
| 14 | Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension (PAH): Too Hot to Handle?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2022</b> ,                                    | 5.7  |   |
| 13 | Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension. <i>European Respiratory Journal</i> , 2102356  | 13.6 | 2 |
| 12 | Salt-inducible kinases: new players in pulmonary arterial hypertension?. <i>Trends in Pharmacological Sciences</i> , <b>2022</b> ,  | 13.2 | 0 |
| 11 | Metabolic reprogramming: A novel metabolic model for pulmonary hypertension. 9,   |      |   |
| 10 | 18 $\beta$ -glycyrrhetic acid ameliorates endoplasmic reticulum stress-induced inflammation in pulmonary arterial hypertension through PERK/eIF2 $\alpha$ /NF- $\kappa$ B signaling. <b>2022</b> , 65, 187                      |      | 0 |
| 9  | Pulmonary Arterial Hypertension in an Infant. <b>2022</b> , 389-392   |      | 0 |
| 8  | Translational Potential of Targeting Anoctamin-1-Encoded Calcium-Activated Chloride Channels in Hypertension. <b>2022</b> , 115320  |      | 0 |
| 7  | Hypoxia-induced pulmonary hypertension upregulates eNOS and TGF- $\beta$ 1 contributing to sex-linked differences in BMPR2 +/R899X mutant mice. <b>2022</b> , 12,   |      | 0 |
| 6  | Pursuing Functional Biomarkers in Complex Disease: Focus on Pulmonary Arterial Hypertension. <b>2022</b> ,  |      | 0 |
| 5  | Analysis of m7G methylation modification patterns and pulmonary vascular immune microenvironment in pulmonary arterial hypertension. 13,  |      | 0 |
| 4  | Lung Cancer Gene Regulatory Network of Transcription Factors Related to the Hallmarks of Cancer. <b>2023</b> , 45, 434-464  |      | 1 |
| 3  | Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension. 4295-4319   |      | 0 |
| 2  | Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models.  |      | 0 |

- 1 Activation of PPAR- $\alpha$  prevents TERT-mediated pulmonary vascular remodeling in MCT-induced pulmonary hypertension. **2023**, 9, e14173

o